Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Brief description of study

The purpose of this study is to see if 3.0mg liraglutide (Saxenda®) is safe and able to help patients achieve weight loss after experiencing weight regain at least 18 months following Roux-en-Y Gastric Bypass (RYGB). Liraglutide (Saxenda®) is approved by the US Food and Drug Administration (FDA) as an add-on therapy to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients who are either obese (with a body mass index (BMI) of 30 kg/m2 or more) or overweight (with a BMI of 27 kg/m2 or more) and have at least one weight-related condition such as high blood pressure, Type 2 diabetes, or dyslipidemia (high triglycerides, high “bad” cholesterol or low “good” cholesterol). Liraglutide (Saxenda®) will be used based on its approved labeling and recommended dose in this study. You may qualify for this study if you had a weight loss surgery called gastric bypass surgery at least 18 months ago and then regained some of the weight you lost.


Clinical Study Identifier: s16-01527
ClinicalTrials.gov Identifier: NCT03048578
Principal Investigator: Holly F Lofton
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.